Judgment of the General Court (Eighth Chamber) of 2 March 2022.#Debregeas et associés Pharma (D & A Pharma) v European Commission and European Medicines Agency.#Medicinal products for human use – Application for conditional marketing authorisation for the medicinal product Hopveus – sodium oxybate – Decision of refusal by the Commission – Regulation (EC) No 726/2004 – Procedure – Committee for Medicinal Products for Human Use – Request for consultation of a specific scientific advisory group – Impartiality of members of an ad hoc committee of experts – Manifest errors of assessment – Equal treatment.#Case T-556/20.

Judgment of the General Court (Eighth Chamber) of 2 March 2022.
Debregeas et associés Pharma (D & A Pharma) v European Commission and European Medicines Agency.
Medicinal products for human use – Application for conditional marketing authorisation for the medicinal product Hopveus – sodium oxybate – Decision of refusal by the Commission – Regulation (EC) No 726/2004 – Procedure – Committee for Medicinal Products for Human Use – Request for consultation of a specific scientific advisory group – Impartiality of members of an ad hoc committee of experts – Manifest errors of assessment – Equal treatment.
Case T-556/20.

Judgment of the General Court (Eighth Chamber) of 2 March 2022.
Debregeas et associés Pharma (D & A Pharma) v European Commission and European Medicines Agency.
Medicinal products for human use – Application for conditional marketing authorisation for the medicinal product Hopveus – sodium oxybate – Decision of refusal by the Commission – Regulation (EC) No 726/2004 – Procedure – Committee for Medicinal Products for Human Use – Request for consultation of a specific scientific advisory group – Impartiality of members of an ad hoc committee of experts – Manifest errors of assessment – Equal treatment.
Case T-556/20.

ECLI identifier: ECLI:EU:T:2022:111